We are live on ! Find out more
AIM icon

AIM ImmunoTech
AIM

14 hedge funds and large institutions have $3.91M invested in AIM ImmunoTech in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

430% more capital inflows, than outflows

Capital inflows: $292K | Capital outflows: $55.2K

0.27% more ownership

Funds ownership: 6.16% → 6.42% (+0.27%)

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock Institutional Trust
BlackRock Institutional Trust
California
+$123K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$92.3K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$30.8K
4
Piper Sandler & Co
Piper Sandler & Co
Minnesota
+$15.4K
5
Renaissance Technologies
Renaissance Technologies
New York
+$15.4K

Top Sellers

Rank Fund Capital Flow
1
Guggenheim Capital
Guggenheim Capital
Illinois
-$30.8K
2
UBS
UBS
Switzerland
-$15.4K
3
Two Sigma Investments
Two Sigma Investments
New York
-$9K

AIM Hedge Fund Activity: Q3 2014 in Review

14 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2014, worth a combined $3.91M — up 12% from $3.51M a quarter earlier.

Fund positioning in AIM was balanced in Q3 2014: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock Institutional Trust, adding an estimated $123K. The largest seller was Guggenheim Capital, exiting entirely with an estimated $30.8K sold.

  • 14 institutional investors held AIM ImmunoTech (AIM) as of Q3 2014, unchanged from Q2 2014.
  • Funds reported $3.91M of AIM ImmunoTech stock for Q3 2014, up 12% quarter-over-quarter.
  • 3 funds opened new AIM ImmunoTech positions in Q3 2014 and 3 closed out, a net change of 0 holders.
  • The largest AIM ImmunoTech buyer in Q3 2014 was BlackRock Institutional Trust, an estimated $123K added.
  • The largest AIM ImmunoTech seller in Q3 2014 was Guggenheim Capital, an estimated $30.8K sold.

Based on aggregated 13F filings for Q3 2014.